| |
著者: Philippe Solal-Céligny, Pascal Roy, Philippe Colombat, Josephine White, Jim O Armitage, Reyes Arranz-Saez, Wing Y Au, Monica Bellei, Pauline Brice, Dolores Caballero, Bertrand Coiffier, Eulogio Conde-Garcia, Chantal Doyen, Massimo Federico, Richard I Fisher, Javier F Garcia-Conde, Cesare Guglielmi, Anton Hagenbeek, Corinne Haïoun, Michael LeBlanc, Andrew T Lister, Armando Lopez-Guillermo, Peter McLaughlin, Noël Milpied, Pierre Morel, Nicolas Mounier, Stephen J Proctor, Ama Rohatiner, Paul Smith, Pierre Soubeyran, Hervé Tilly, Umberto Vitolo, Pier-Luigi Zinzani, Emanuele Zucca, Emili Montserrat
雑誌名: Blood. 2004 Sep 1;104(5):1258-65. doi: 10.1182/blood-2003-12-4434. Epub 2004 May 4.
Abstract/Text
The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help in evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs < or = 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs > or = 120 g/L), number of nodal areas (> 4 vs < or = 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36% of patients), intermediate risk (2 factors, 37% of patients, hazard ratio [HR] of 2.3), and poor risk (> or = 3 adverse factors, 27% of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments.
PMID 15126323 Blood. 2004 Sep 1;104(5):1258-65. doi: 10.1182/blood-2003-12-4434. Epub 2004 May 4.
|
